The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
Open accessAbstract
BACKGROUND: Mutations in the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) play a critical role in cancer cell growth and resistance to therapy. Most mutations occur at codons 12 and 13. In colorectal cancer, the presence of any mutant KRas amino acid substitution is a negative predictor of patient response to targeted therapy. However, in non-small cell lung cancer (NSCLC), the evidence that KRAS mutation is a predictive factor is conflicting. METHODS: We used data from a molecularly targeted clinical trial for 215 patients with tissues available out of 268 evaluable patients with refractory NSCLC to examine associations between specific mutant KRas proteins and progression-free survival and tumor gene expression. Transcriptome microarray studies of patient tumor samples and reverse-phase protein array studies of a panel of 67 NSCLC cell lines with known substitutions in KRas and in immortalized human bronchial epithelial cells stably expressing different mutant KRas proteins were used to investigate signaling pathway activation. Molecular modeling was used to study the conformations of wild-type and mutant KRas proteins. Kaplan-Meier curves and Cox regression were used to analyze survival data. All statistical tests were two-sided. RESULTS: Patients whose tumors had either mutant KRas-Gly12Cys or mutant KRas-Gly12Val had worse progression-free survival compared with patients whose tumors had other mutant KRas proteins or wild-type KRas (P = .046, median survival = 1.84 months) compared with all other mutant KRas (median survival = 3.35 months) or wild-type KRas (median survival = 1.95 months). NSCLC cell lines with mutant KRas-Gly12Asp had activated phosphatidylinositol 3-kinase (PI-3-K) and mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) signaling, whereas those with mutant KRas-Gly12Cys or mutant KRas-Gly12Val had activated Ral signaling and decreased growth factor-dependent Akt activation. Molecular modeling studies showed that different conformations imposed by mutant KRas may lead to altered association with downstream signaling transducers. CONCLUSIONS: Not all mutant KRas proteins affect patient survival or downstream signaling in a similar way. The heterogeneous behavior of mutant KRas proteins implies that therapeutic interventions may need to take into account the specific mutant KRas expressed by the tumor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is notable that STK11 loss of function mutations that dysregulate mTOR are enriched and occur in approximately one third of KRAS -mutated NSCLC and that PIK3CA and PTEN mutations are significantly mutually exclusive with KRAS mutations in NSCLC [35].”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [35]
In the citing paper
“All these factors contribute to the heterogeneous and cancer-type-specific resistance mechanisms [163].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [163]
In the citing paper
“Additional biochemical, structural, and signaling distinctions have been identified between different mutant alleles, including between those at the same amino acid position4,8,13–20.”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [17]
In the citing paper
“This reaction enables differential, mutant-specific associations with downstream signaling transducers, which have previously been characterized to be important for Kras mutant variants in the non-small cell lung cancer context (Ihle et al., 2012).”
From Efficient Parameter Estimation Enables the Prediction of Drug Response Using a Mechanistic Pan-Cancer Pathway Model (2018) · cites this paper as Ihle et al., 2012
In the citing paper
“G12C and G12V mutations are shown to preferentially activate RAL signaling and G12D-mutant cell lines are shown to have high levels of phosphorylated AKT, suggesting preferential activation of PI3K-AKT-mTOR pathway [46, 47].”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [46]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Scalable molecular dynamics with NAMD
Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R. D., Kalé, L., & Schulten, K. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20289 · Cited by 16,914
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Kim, E. S., Herbst, R. S., Wistuba, I. I., Lee, J. J., Blumenschein, G. R., Tsao, A., Stewart, D. J., Hicks, M. E., Erasmus, J., Gupta, S., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0010 · Cited by 889
Self-citationTuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798
Kirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study
Andreyev, H. J. N., Norman, A. R., Clarke, P. A., Cunningham, D., & Oates, J. R. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.675 · Cited by 748
Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ
Pacold, M. E., Suire, S., Perisic, O., Lara-Gonzalez, S., Davis, C. T., Walker, E. H., Hawkins, P. T., Stephens, L., Eccleston, J. F., & Williams, R. L. (2000) · Cell · doi:10.1016/s0092-8674(00)00196-3 · Cited by 602
ZRANK: Reranking protein docking predictions with an optimized energy function
Pierce, B., & Weng, Z. (2007) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.21373 · Cited by 444
Distinct requirements for Ras oncogenesis in human versus mouse cells
Hamad, N. M., Elconin, J. H., Karnoub, A. E., Bai, W., Rich, J. N., Abraham, R. T., Der, C. J., & Counter, C. M. (2002) · Genes & Development · doi:10.1101/gad.993902 · Cited by 431
Sullivan, J. P., Spinola, M., Dodge, M., Raso, M. G., Behrens, C., Gao, B., Schuster, K., Shao, C., Larsen, J. E., Sullivan, L. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0881 · Cited by 416
Self-citationScalable Molecular Dynamics with NAMD
Phillips, J. C., Schulten, K., Bhatele, A. S., Mei, C., Sun, Y., & Kalé, L. V. (2012) · University of North Texas Digital Library (University of North Texas) · Cited by 365
Cited by
Moffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., et al. (2015) · Nature Genetics · doi:10.1038/ng.3398 · Cited by 2,194
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115
KRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019
Self-citation
Metadata
- Authors
- Ihle, N. T., Byers, L. A., Kim, E. S., Saintigny, P., Lee, J. J., Blumenschein, G. R., Tsao, A., Liu, S., Larsen, J. E., Wang, J., Diao, L., Coombes, K. R., Chen, L., Zhang, S., Abdelmelek, M. F., Tang, X., Papadimitrakopoulou, V., Minna, J. D., Lippman, S. M., Hong, W. K., Herbst, R. S., Wistuba, I. I., Heymach, J. V., & Powis, G.
- Affiliations
- Harold C. Simmons Comprehensive Cancer Center (US)
- ORCID
- Ihle, Nathan T.
- Byers, Lauren A.
- Kim, Edward S.
- Saintigny, Pierre
- Blumenschein, George R.
- Tsao, Anne
- Liu, Suyu
- Larsen, Jill E.
- Wang, Jing
- Diao, Lixia
- Coombes, Kevin R.
- Chen, Lu
- Zhang, Shuxing
- Papadimitrakopoulou, Vassiliki
- Minna, John D.
- Lippman, Scott M.
- Hong, Waun K.
- Herbst, Roy S.
- Wistuba, Ignacio I.
- Heymach, John V.
- Powis, Garth
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-01-13
- Volume
- 104
- Issue
- 3
- Pages
- 228-239
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- PMC
- PMC3274509
- OpenAlex
- W2166923287
- Cited by
- 532
- References
- 31
- Citations by year
- 2026: 23 · 2025: 32 · 2024: 41 · 2023: 32 · 2022: 45 · 2021: 49 · 2020: 40 · 2019: 38 · 2018: 37 · 2017: 25 · 2016: 42 · 2015: 48 · 2014: 31 · 2013: 28 · 2012: 21
- FWCI
- 32.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- U.S. Department of Defense (W81XWH, W81XWH-6-1-0303)
- National Institutes of Health (W81XWH, CA- 016672)
- University of Texas MD Anderson Cancer Center ((CA016672), P30-CA-016672)
- National Cancer Institute (R01CA155196, R01CA160398, CA155196, P50CA070907, CA160398, P30CA016672)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- KRAS mutation, non-small cell lung cancer, progression-free survival, predictive biomarkers, PI3K signaling, MEK signaling, Akt activation, protein conformation, targeted therapy, colorectal cancer
- MeSH terms
- Aspartic Acid, Carcinoma, Non-Small-Cell Lung, Cysteine, Genetic Vectors, Glycine, Humans, Lung Neoplasms, Mutation, Genes, ras, Valine, Immunoblotting, Signal Transduction, Gene Expression Regulation, Neoplastic, Randomized Controlled Trials as Topic, Lentivirus, Treatment Outcome, Clinical Trials, Phase II as Topic, Disease-Free Survival, Gene Expression Profiling, Cell Line, Tumor, Microarray Analysis, Immunoprecipitation, Proto-Oncogene Proteins c-akt, Kaplan-Meier Estimate, TOR Serine-Threonine Kinases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome. https://app.cochat.ai/papers/10.1093/jnci/djr523
- The paper
- Ihle, N. T., Byers, L. A., Kim, E. S., Saintigny, P., Lee, J. J., Blumenschein, G. R., Tsao, A., Liu, S., Larsen, J. E., Wang, J., Diao, L., Coombes, K. R., Chen, L., Zhang, S., Abdelmelek, M. F., Tang, X., Papadimitrakopoulou, V., Minna, J. D., Lippman, S. M., . . . Powis, G. (2012). Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djr523
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.